Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 17, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

View original at globenewswire.com
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel sou…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI-Immunology™ is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens, which holds great potential for improving vaccine efficacy

    60% confidence

  • AI-Immunology™ can be applied across a range of different cancers as well as other diseases

    60% confidence

  • There is a dire need for better treatment options for glioblastoma, which is refractory to immunotherapy due to low mutational burden and paucity of canonical neoantigens. ERVs constitute a new tumor-specific antigen source that can be targeted by vaccines alongside mutation-derived epitopes

    60% confidence

  • In addition to ERV-derived antigens, neoantigens of sufficient quality to include in a vaccine were identified in the majority of patients

    60% confidence

  • ERVs constitute a relevant antigen source that may overcome limitations imposed by low mutational burden, providing a strong Proof-of-Concept for personalized vaccines incorporating ERV-derived antigens

    60% confidence

  • AI-Immunology™ has unique capabilities in identifying ERVs, opening a whole new source of antigens which can potentially greatly improve the efficacy of cancer vaccines for glioblastoma patients who generally have few neoantigens to target due to low mutational burden

    60% confidence

  • ERVs are tumor antigens from the dark genome that are present in tumors but absent in normal tissue, making them highly attractive targets for cancer vaccines

    60% confidence

Cited in these Via News reports